Uriel Sandkovsky
A5057455263- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- HIV Research and Treatment
- Long-Term Effects of COVID-19
- Cytomegalovirus and herpesvirus research
- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV-related health complications and treatments
- SARS-CoV-2 detection and testing
- HIV, Drug Use, Sexual Risk
- Antifungal resistance and susceptibility
- Mechanical Circulatory Support Devices
- Reproductive tract infections research
- Adolescent Sexual and Reproductive Health
- Herpesvirus Infections and Treatments
- Infective Endocarditis Diagnosis and Management
- Viral gastroenteritis research and epidemiology
- Streptococcal Infections and Treatments
- Functional Brain Connectivity Studies
- Parvovirus B19 Infection Studies
- Intensive Care Unit Cognitive Disorders
- Nosocomial Infections in ICU
- Medication Adherence and Compliance
- Burn Injury Management and Outcomes
Baylor University Medical Center
2019-2025
Aurora Health Care
2023
Infectious Disease Consultants
2021-2022
Baylor Scott & White Health
2020-2022
Baylor University
2020-2022
Duke University
2021
University of Copenhagen
2020
Rigshospitalet
2020
Gentofte Hospital
2020
Aarhus University Hospital
2020
BackgroundSevere coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment baricitinib, a Janus kinase inhibitor, plus remdesivir are not known.MethodsWe conducted double-blind, randomized, placebo-controlled trial evaluating baricitinib in hospitalized adults Covid-19. All the patients received (≤10 days) and either (≤14 or placebo (control). primary outcome was time to recovery. key secondary clinical status at day 15.ResultsA...
Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was recently approved in the United States for treatment of human immunodeficiency virus type 1 (HIV-1) infection combination with other antiretroviral agents. Dolutegravir, abacavir-lamivudine, may provide simplified regimen.We conducted randomized, double-blind, phase 3 study involving adult participants who had not received previous therapy HIV-1 and an RNA level 1000 copies per milliliter or more. Participants were...
BackgroundLY-CoV555, a neutralizing monoclonal antibody, has been associated with decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients coronavirus disease 2019 (Covid-19). Data are needed on effect this antibody patients who hospitalized Covid-19.MethodsIn platform trial therapeutic agents, we randomly assigned had Covid-19 without end-organ failure 1:1 ratio to receive either LY-CoV555 matching placebo. In addition, all received...
In a randomized, placebo-controlled, clinical trial, bamlanivimab, SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients COVID-19 based on an early futility assessment.
Acinetobacter baumannii (Ab) is a frequent cause of hospital acquired pneumonia and recently has increased in incidence as the causative agent severe disease troops wounded Afghanistan Iraq. Ab clinical isolates are frequently extremely resistant to antimicrobials, significantly complicating our capacity treat infections due this pathogen. Hence, development innovative therapeutics targeting mechanisms which bacteria unlikely evolve resistance urgently needed. We examined nitric oxide...
Aim: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy. Methods: Four hundred adult HIV-infected patients currently prescribed therapy were surveyed. χ2 tests used for comparisons of across groups. Results: Respondents 68% male and 53% African–American, with a mean age 47 years. Overall, 73% indicated that they would definitely or probably try therapy; 61% weekly dosing; 72% every 2 weekly; 84% monthly. In total, 48% very concerned about the...
Abstract Background Persistent mortality in adults hospitalized due to acute COVID-19 justifies pursuit of disease mechanisms and potential therapies. The aim was evaluate which virus host response factors were associated with risk among participants Therapeutics for Inpatients (TICO/ACTIV-3) trials. Methods A secondary analysis 2625 SARS-CoV-2 infection randomized 1 5 antiviral products or matched placebo 114 centers on 4 continents. Uniform, site-level collection participant baseline...
Combination antiretroviral therapy transformed human immunodeficiency virus (HIV)-infection from a terminal illness to manageable condition, but these patients remain at significantly elevated risk of developing cognitive impairments and the mechanisms are not understood. Some previous neuroimaging studies have found hyperactivation in frontoparietal networks HIV-infected patients, whereas others reported aberrations restricted sensory cortices. In this study, we utilize high-resolution...
Ensovibep (MP0420) is a designed ankyrin repeat protein, novel class of engineered proteins, under investigation as treatment SARS-CoV-2 infection.To investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared care alone.Double-blind, randomized, placebo-controlled, trial. (ClinicalTrials.gov: NCT04501978).Multinational, multicenter trial.Adults COVID-19.Intravenous 600 mg, or placebo.Ensovibep was...
Background/aims Safe and effective therapies for COVID-19 are urgently needed. In order to meet this need, the Accelerating Therapeutic Interventions Vaccines public–private partnership initiated Therapeutics Inpatients with COVID-19. is a multi-arm, multi-stage platform master protocol, which facilitates rapid evaluation of safety efficacy novel candidate antiviral therapeutic agents adults hospitalized Five have so far entered answers already provided three these. Other expected enter...
Objective Shortly after infection, HIV enters the brain and causes widespread inflammation neuronal damage, which ultimately leads to neuropsychological impairments. Despite a large body of neuroscience imaging studies, pathophysiology these HIV-associated neurocognitive disorders (HAND) remains unresolved. Previous neuroimaging studies have shown greater activation in HIV-infected patients during strenuous tasks frontal parietal cortices, less primary sensory cortices rest stimulation....